Lysine for Cats: Evidence, Safety, and Feline Herpesvirus Claims
What lysine supplements for cats are marketed to do
Lysine is an essential amino acid, meaning cats need to obtain it through their diet. Commercial lysine products for cats are commonly marketed as providing immune, respiratory, or eye support, particularly for cats with suspected or recurrent feline herpesvirus type 1 (FHV-1) disease.
The marketing often reflects a proposed antiviral effect rather than established clinical benefit. The theory was that giving extra lysine might interfere with the availability or use of another amino acid, arginine, and in turn limit FHV-1 replication. A nutrient's normal role in the diet does not show that taking additional amounts will prevent or treat a viral infection.
Products may therefore describe lysine as supportive care for cats with sneezing, congestion, eye discharge, or other respiratory and ocular signs. Those descriptions should be treated as product claims, not as proof that supplementation prevents infection, controls viral shedding, shortens illness, or reduces the severity of disease. A cat may also improve after starting a supplement for reasons unrelated to the supplement, including the natural course of illness or changes in other aspects of care.
The key distinction is between nutritional adequacy and therapeutic effect. Cats require lysine as part of normal nutrition, but the available feline evidence does not establish that adding lysine provides a reliable clinical advantage against FHV-1.
Does lysine help cats with feline herpesvirus?
The best-supported answer from the cited evidence is no: lysine supplementation has not been shown consistently to prevent or treat FHV-1 infection in cats. A systematic review of seven studies, including five involving cats, concluded that the available evidence did not support lysine for either purpose.
Across the feline studies, supplementation did not consistently reduce infection, viral shedding, the frequency of eye or upper-respiratory disease, symptom severity, or recovery time. Some early or small studies reported potentially favorable findings, which helped establish lysine's popularity. But those signals were not reproduced consistently across the broader feline clinical evidence.
When interpreting individual experiences. An owner may observe improvement after giving lysine, but an anecdote cannot determine whether the supplement caused the change. FHV-1-related signs may fluctuate, and cats may receive other care at the same time. Temporary improvement is therefore not evidence of a dependable treatment effect.
The lack of demonstrated benefit also does not mean that every cat given lysine will be harmed. Some studies reported more frequent infection or more severe disease among supplemented cats, but those observations do not prove that lysine caused worse outcomes. The evidence supports caution about expecting benefit rather than a conclusion that supplementation is uniformly dangerous.
What the feline studies found
The feline research did not show a consistent benefit across the outcomes that would matter clinically. Lysine did not reliably inhibit FHV-1 replication under relevant conditions, reduce viral shedding, prevent infection, or lower the frequency or severity of ocular and upper-respiratory signs. It also did not consistently shorten recovery.
Limited positive findings from small studies were not reproduced consistently. Differences among the studies-including the amount of lysine, formulation, schedule, diet, cat population, and experimental conditions-make isolated results difficult to generalize. A favorable result in one setting is not the same as a reproducible treatment effect.
Some studies raised a different concern by reporting more frequent infection or more severe disease in supplemented cats. These findings should be described accurately but cautiously. They do not establish that lysine caused the outcomes, particularly when study conditions may have affected the cats independently.
One 52-day study of 50 group-housed cats illustrates this limitation. Cats receiving a diet with a higher lysine content had higher mean disease scores and more detections of FHV-1 DNA than cats receiving the lower-lysine diet. Aggression and stress were concentrated in one supplemented male group, and the study authors stated that the data did not permit a definitive conclusion about efficacy. The result therefore does not prove that lysine worsened disease, but it also does not provide evidence of a useful protective effect.
Lysine Supplements and Feline Herpesvirus: What the Evidence Shows
Why the lysine-and-arginine theory is unconvincing
The proposed explanation for lysine supplementation was that extra lysine would lower arginine availability and thereby restrict FHV-1 replication. This mechanism was biologically plausible enough to attract interest, but plausibility is not the same as demonstrated antiviral activity in cats.
The reviewed feline evidence did not establish that supplemental lysine creates an effective lysine-arginine imbalance or inhibits FHV-1 replication under physiologically relevant conditions. Without a reproducible effect on viral replication or clinical outcomes, the mechanism cannot serve as evidence that supplementation works in practice.
Arginine also has an essential nutritional role in cats. It is required for ammonia disposal through the urea cycle, and experimental diets lacking arginine can cause hyperammonemia and potentially fatal illness. That is why deliberately restricting arginine in an attempt to affect FHV-1 would be inappropriate.
This warning should not be reversed into an unsupported claim that ordinary lysine supplementation has been proven to cause arginine deficiency, hyperammonemia, or death. The evidence supplied does not establish that conclusion. The relevant point is narrower: arginine restriction is dangerous, and the proposed mechanism does not justify manipulating a cat's diet in that direction.
Product forms, labels, and the dosage problem
Lysine for cats is sold in several formats, including powders, gels, pastes, chews, and fortified foods. Labels commonly present serving directions and may describe immune, respiratory, or eye support. Those descriptions do not establish that the product prevents or treats FHV-1.
There is no evidence-based universal lysine dose or reliable time-to-benefit for cats with FHV-1. Published studies used different amounts, formulations, schedules, diets, cat populations, and experimental conditions. Because efficacy was not established, the regimens used in those studies do not define a standard treatment protocol.
A serving direction on one product should not be transferred to another. Products can differ in concentration, ingredients, and formulation. An amount used in an experiment should not be converted into a recommendation for routine use, a kitten dose, a treatment duration, or an expected time for improvement.
Owners considering a product should read the complete label and discuss its intended purpose with a veterinarian, especially when the cat has active signs or other health concerns. The central question is not simply how much lysine a product contains, but whether supplementation has a demonstrated role in the cat's situation. Current evidence does not establish that it does for prevention or treatment of FHV-1.
Safety limitations and cats needing veterinary guidance
Tolerability and efficacy are separate questions. A cat may appear to tolerate a product, or a product may be easy to administer, without evidence that it treats FHV-1. The available evidence does not support creating a universal safety rule for every cat or every commercial formulation.
The supplied evidence does not establish comprehensive safety guidance for kittens, pregnant or nursing cats, cats with chronic disease, or cats taking medication. It also does not provide universal adverse-effect rates, interaction rules, contraindications, or monitoring schedules for lysine products. These limitations make product-specific veterinary review more appropriate than relying on a general label claim.
Veterinary input is particularly important when a cat is already ill, has recurring eye or respiratory problems, is eating poorly, or has other medical conditions. A supplement should not replace diagnosis, prescribed treatment, or clinician-directed care. Owners already using lysine should discuss why it was started and whether continued use makes sense rather than changing prescribed care based solely on marketing claims or an article.
The evidence also does not justify assuming that lysine is either universally harmless or necessarily harmful. Its clinical usefulness for FHV-1 remains unproven, while individualized safety questions depend on the product and the cat.
What to do when a cat has respiratory or eye signs
Sneezing, congestion, nasal or ocular discharge, inflammation of the eyes or nasal passages, lethargy, and reduced appetite can occur with active FHV-1 infection. These signs do not by themselves prove that FHV-1 is the cause. Similar signs can occur in other situations, so a supplement cannot establish the diagnosis.
When a cat develops active respiratory or eye signs, veterinary assessment is more appropriate than relying on lysine as treatment. This is especially important when the cat is lethargic, eating less, or has noticeable eye or nasal discharge. The systematic review specifically recommends veterinary examination for cats showing signs of active infection rather than depending on lysine supplementation.
A product marketed for respiratory or eye support should not be treated as a substitute for evaluation. The label may describe intended benefits, but those claims do not confirm the cause of the signs or show that the product will control the illness. Delaying assessment while waiting for an unproven supplement to work can leave the underlying problem unaddressed.
Owners should also avoid using the presence or absence of improvement after starting lysine as a diagnostic test. Improvement does not prove that lysine was effective, and persistence or worsening of signs should not be managed by simply increasing or extending supplementation without veterinary guidance.
The practical bottom line for cat owners
Lysine remains widely marketed for immune, respiratory, and eye support in cats, especially in connection with FHV-1. But the cited systematic review and feline clinical evidence do not establish supplemental lysine as an effective way to prevent or treat FHV-1 infection.
The evidence does not provide a universal dose or dependable time-to-benefit. Early positive findings were limited and were not consistently reproduced. Reports of worse outcomes in some studies should not be overstated as proof that lysine causes disease, particularly where stress or group effects could have influenced the results. Biological plausibility, popularity, or apparent tolerability is not a substitute for demonstrated clinical benefit.
For a cat with sneezing, discharge, eye inflammation, lethargy, or reduced appetite, veterinary assessment should take priority over relying on a supplement. Owners already giving lysine can discuss its purpose and continued use with their veterinarian, without changing prescribed care solely because of information in this article.
Lysine should be viewed as an unproven supplement for FHV-1 rather than an established preventive or treatment. Normal dietary lysine is part of feline nutrition, but that does not show that additional lysine improves the course of a viral infection.
Lysine is essential for cats, but products marketed for immune, respiratory, or eye support often target feline herpesvirus type 1 disease, and the main practical question is whether extra lysine helps. The best-supported answer is no: a systematic review of seven studies, including five in cats, concluded that available evidence did not support lysine for prevention or treatment of FHV-1. Feline studies did not consistently show less infection, reduced viral shedding, fewer or milder eye and upper-respiratory signs, or faster recovery. Early positive findings were not reproduced, and reports of more frequent infection or more severe disease in some supplemented cats do not prove lysine caused harm.
There is no evidence-based universal dose or reliable time-to-benefit, and product labels, serving directions, or apparent tolerability are not proof of benefit. Safety guidance is limited for kittens, pregnant or nursing cats, cats with chronic disease, or cats taking medication. For cats with active sneezing, congestion, discharge, eye inflammation, lethargy, or reduced appetite, veterinary assessment should take priority over relying on a supplement. The proposed arginine-restriction mechanism was not established, and deliberately restricting arginine would be inappropriate because arginine is essential. Lysine should be viewed as an unproven supplement for FHV-1, not an established preventive or treatment.
Publishing organization: BMC Veterinary Research
Publishing organization: European Advisory Board on Cat Diseases
Publishing organization: Merck Veterinary Manual
Questions and comments
Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.